{"id":450441,"date":"2021-03-04T07:03:48","date_gmt":"2021-03-04T12:03:48","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450441"},"modified":"2021-03-04T07:03:48","modified_gmt":"2021-03-04T12:03:48","slug":"medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/","title":{"rendered":"Medicenna Therapeutics to Present at Upcoming March Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">TORONTO and HOUSTON, March  04, 2021  (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.\u00a0Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,\u00a0will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31<sup>st<\/sup> Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference. All three virtual investor conferences will take place in March 2021.<\/p>\n<p>Details are as follows:<\/p>\n<p>\n        <strong>H.C. Wainwright Global Life Sciences Conference<\/strong><br \/>\n        <br \/>Format: Pre-Recorded Presentation<br \/>Date: Available on-demand starting at 7 am ET on Tuesday, March 9, 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Oppenheimer 31<\/strong><br \/>\n        <sup><br \/>\n          <strong>st<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Healthcare Conference <\/strong><br \/>\n        <br \/>Format: Live Presentation<br \/>Date: Wednesday, March 17<br \/>Time: 2:30 pm ET<\/p>\n<p>\n        <strong>Maxim 2021 Emerging Growth Virtual Conference <\/strong><br \/>\n        <br \/>Format: Live Glioblastoma Panel Discussion and Pre-Recorded Presentation<br \/>Date: Wednesday, March 17<br \/>Time: 11:00 am ET<\/p>\n<p>Webcast and replay links and further information for these events will be available on the Investor Relations section of Medicenna&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=As6AyBrkLw_HmJ_COybi0ZjH21mVzwN5L4yEoNhleyEQcW5Wqru-fWLj0I13yuUaDYOpu42UCjxp3gipL5PM6mXOgv7nb9t1uaUaGgmjdx-6BHDp_MEWaGMJudJqt04evlJd4PKkz9KgCQOj397jxiT6bw1NNBHMwYKOCI4qWo0zM45_6t2nv6gZK-4MmEIycTHMWsZUwIpGUyhyCBfqiHspBPRe1y1PliaMuHbubIcUkbLwUt9gs45D1WUbr7FgAqrmIIITTMAZUtKW9M0BEw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/ir.medicenna.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Medicenna <\/strong><br \/>\n        <br \/>Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna&#8217;s long-acting IL2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna&#8217;s lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA\/EMA, respectively.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking statement <\/strong><br \/>\n        <br \/>This news release contains forward-looking statements under applicable securities laws and relate to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as &#8220;will&#8221;, &#8220;may&#8221;, &#8220;should&#8221;, &#8220;anticipate&#8221;, &#8220;expects&#8221;, &#8220;believes&#8221; and similar expressions. All statements other than statements of historical fact, included in this release, including the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company&#8217;s expectations include the risks detailed in the annual information form of the Company dated\u00a0May 14, 2020\u00a0and in other filings made by the Company with the applicable securities regulators from time to time in\u00a0Canada\u00a0and\u00a0the United States.<\/p>\n<p align=\"justify\">The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all subjects and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian and\u00a0United States\u00a0securities law.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/333db2fb-7bf8-4ad5-9ff7-865f13c78b0d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Further Information\r\n\r\nFor further information about the Company please contact:\r\n\r\nElizabeth Williams, Chief Financial Officer, 416-648-5555, ewilliams@medicenna.com\u00a0\u00a0\u00a0\r\n\r\nInvestor Contact\r\n\r\nFor more investor information, please contact:\r\n\r\nDan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, daniel@lifesciadvisors.com\u00a0<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.\u00a0Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,\u00a0will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference. All three virtual investor conferences will take place in March 2021. Details are as follows: H.C. Wainwright Global Life Sciences Conference Format: Pre-Recorded PresentationDate: Available on-demand starting at 7 am ET on Tuesday, March 9, 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oppenheimer 31 st Annual Healthcare Conference Format: Live PresentationDate: Wednesday, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Medicenna Therapeutics to Present at Upcoming March Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450441","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Medicenna Therapeutics to Present at Upcoming March Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicenna Therapeutics to Present at Upcoming March Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.\u00a0Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,\u00a0will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference. All three virtual investor conferences will take place in March 2021. Details are as follows: H.C. Wainwright Global Life Sciences Conference Format: Pre-Recorded PresentationDate: Available on-demand starting at 7 am ET on Tuesday, March 9, 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oppenheimer 31 st Annual Healthcare Conference Format: Live PresentationDate: Wednesday, &hellip; Continue reading &quot;Medicenna Therapeutics to Present at Upcoming March Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T12:03:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medicenna Therapeutics to Present at Upcoming March Investor Conferences\",\"datePublished\":\"2021-03-04T12:03:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/\"},\"wordCount\":638,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/\",\"name\":\"Medicenna Therapeutics to Present at Upcoming March Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=\",\"datePublished\":\"2021-03-04T12:03:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicenna Therapeutics to Present at Upcoming March Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicenna Therapeutics to Present at Upcoming March Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Medicenna Therapeutics to Present at Upcoming March Investor Conferences - Market Newsdesk","og_description":"TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or \u201cthe Company\u201d) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr.\u00a0Fahar Merchant, President, CEO and Chairman of the Board of Medicenna,\u00a0will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021 Emerging Growth Virtual Conference. All three virtual investor conferences will take place in March 2021. Details are as follows: H.C. Wainwright Global Life Sciences Conference Format: Pre-Recorded PresentationDate: Available on-demand starting at 7 am ET on Tuesday, March 9, 2021\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Oppenheimer 31 st Annual Healthcare Conference Format: Live PresentationDate: Wednesday, &hellip; Continue reading \"Medicenna Therapeutics to Present at Upcoming March Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T12:03:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medicenna Therapeutics to Present at Upcoming March Investor Conferences","datePublished":"2021-03-04T12:03:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/"},"wordCount":638,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/","name":"Medicenna Therapeutics to Present at Upcoming March Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=","datePublished":"2021-03-04T12:03:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDE1MiM0MDQ3ODEyIzIxMjI0ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicenna-therapeutics-to-present-at-upcoming-march-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medicenna Therapeutics to Present at Upcoming March Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450441"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450441\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}